Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klebsiella pneumoniae | 5 | 2020 | 85 | 0.890 |
Why?
|
| beta-Lactamases | 5 | 2020 | 208 | 0.690 |
Why?
|
| Tuberculosis, Pulmonary | 8 | 2009 | 229 | 0.640 |
Why?
|
| Bacterial Proteins | 6 | 2020 | 930 | 0.610 |
Why?
|
| Guinea Pigs | 13 | 2009 | 161 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 12 | 2024 | 2554 | 0.530 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2024 | 827 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 664 | 0.470 |
Why?
|
| Candidemia | 4 | 2023 | 44 | 0.470 |
Why?
|
| BCG Vaccine | 6 | 2007 | 112 | 0.440 |
Why?
|
| Klebsiella Infections | 4 | 2017 | 60 | 0.430 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 104 | 0.410 |
Why?
|
| beta-Lactam Resistance | 1 | 2013 | 48 | 0.410 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2018 | 382 | 0.400 |
Why?
|
| Cephalosporins | 3 | 2024 | 139 | 0.360 |
Why?
|
| Antimicrobial Stewardship | 2 | 2023 | 85 | 0.330 |
Why?
|
| Cross Infection | 4 | 2014 | 342 | 0.330 |
Why?
|
| Candida | 4 | 2023 | 84 | 0.320 |
Why?
|
| Minocycline | 2 | 2022 | 42 | 0.320 |
Why?
|
| Mycobacterium bovis | 2 | 2007 | 32 | 0.290 |
Why?
|
| Antigens, CD | 2 | 2007 | 431 | 0.280 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 270 | 0.270 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2007 | 413 | 0.270 |
Why?
|
| Leukocytes | 3 | 2007 | 209 | 0.260 |
Why?
|
| Drug Utilization | 3 | 2020 | 166 | 0.260 |
Why?
|
| Hospitals, University | 4 | 2014 | 104 | 0.250 |
Why?
|
| Antifungal Agents | 5 | 2023 | 312 | 0.240 |
Why?
|
| Carbapenems | 2 | 2015 | 43 | 0.210 |
Why?
|
| Vaccination | 3 | 2009 | 1018 | 0.200 |
Why?
|
| Eosinophils | 1 | 2004 | 122 | 0.200 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 93 | 0.200 |
Why?
|
| Tuberculosis Vaccines | 3 | 2009 | 13 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1028 | 0.180 |
Why?
|
| Lung | 4 | 2009 | 1555 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2023 | 160 | 0.180 |
Why?
|
| Macrophages, Peritoneal | 3 | 2006 | 39 | 0.170 |
Why?
|
| Doxycycline | 2 | 2022 | 120 | 0.170 |
Why?
|
| Feces | 2 | 2015 | 755 | 0.160 |
Why?
|
| Clostridium Infections | 2 | 2014 | 249 | 0.160 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 131 | 0.160 |
Why?
|
| Ceftazidime | 1 | 2020 | 47 | 0.160 |
Why?
|
| Urine | 1 | 2020 | 90 | 0.160 |
Why?
|
| Candidiasis | 2 | 2023 | 137 | 0.140 |
Why?
|
| Ceftriaxone | 1 | 2018 | 69 | 0.140 |
Why?
|
| Peritonitis | 1 | 2018 | 76 | 0.140 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 4 | 0.130 |
Why?
|
| Bacteremia | 3 | 2017 | 428 | 0.130 |
Why?
|
| Texas | 8 | 2021 | 3627 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 202 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2015 | 133 | 0.130 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 56 | 0.130 |
Why?
|
| Immunization, Secondary | 2 | 2009 | 113 | 0.130 |
Why?
|
| Inpatients | 1 | 2021 | 550 | 0.130 |
Why?
|
| Bacteria | 2 | 2018 | 522 | 0.130 |
Why?
|
| Spleen | 3 | 2007 | 270 | 0.130 |
Why?
|
| Echinocandins | 4 | 2023 | 44 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1743 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 175 | 0.120 |
Why?
|
| Health Personnel | 1 | 2021 | 543 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 317 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 540 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2018 | 323 | 0.110 |
Why?
|
| Fluconazole | 2 | 2012 | 51 | 0.110 |
Why?
|
| Humans | 31 | 2024 | 131924 | 0.110 |
Why?
|
| Meningitis | 1 | 2015 | 100 | 0.110 |
Why?
|
| Gram-Positive Bacteria | 1 | 2014 | 48 | 0.110 |
Why?
|
| Candida glabrata | 1 | 2014 | 19 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1380 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2015 | 176 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 79 | 0.110 |
Why?
|
| Candidiasis, Invasive | 1 | 2014 | 23 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2013 | 47 | 0.100 |
Why?
|
| Fungal Proteins | 1 | 2014 | 135 | 0.100 |
Why?
|
| Rifamycins | 1 | 2013 | 18 | 0.100 |
Why?
|
| Lipopeptides | 3 | 2023 | 36 | 0.100 |
Why?
|
| Peptidomimetics | 1 | 2013 | 12 | 0.100 |
Why?
|
| Biological Therapy | 1 | 2012 | 25 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 73 | 0.090 |
Why?
|
| Macrophage Activation | 3 | 2006 | 65 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1044 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2013 | 470 | 0.080 |
Why?
|
| Intensive Care Units | 3 | 2023 | 523 | 0.080 |
Why?
|
| Animals | 13 | 2009 | 34781 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 1347 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 128 | 0.080 |
Why?
|
| Cross Reactions | 2 | 2007 | 189 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 2669 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 116 | 0.080 |
Why?
|
| Aged | 10 | 2018 | 21385 | 0.070 |
Why?
|
| Tuberculosis, Pleural | 2 | 2005 | 8 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2140 | 0.070 |
Why?
|
| Middle Aged | 11 | 2018 | 28943 | 0.070 |
Why?
|
| Antibody Formation | 2 | 2006 | 274 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2007 | 149 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 724 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2015 | 6569 | 0.060 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 256 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 7097 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 679 | 0.060 |
Why?
|
| Physicians | 1 | 2012 | 641 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 46 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 791 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2005 | 32 | 0.060 |
Why?
|
| Granuloma | 1 | 2005 | 65 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2005 | 121 | 0.050 |
Why?
|
| Phenotype | 1 | 2013 | 4526 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 534 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2003 | 141 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 138 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 1077 | 0.050 |
Why?
|
| Female | 12 | 2018 | 70584 | 0.050 |
Why?
|
| Male | 11 | 2018 | 64870 | 0.050 |
Why?
|
| Vancomycin | 2 | 2014 | 222 | 0.050 |
Why?
|
| Cytokines | 2 | 2005 | 1359 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 293 | 0.050 |
Why?
|
| Adult | 6 | 2023 | 31536 | 0.050 |
Why?
|
| Tuberculosis | 2 | 2005 | 554 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2022 | 162 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 472 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 28 | 0.040 |
Why?
|
| Prevalence | 2 | 2018 | 2658 | 0.040 |
Why?
|
| Azabicyclo Compounds | 1 | 2020 | 19 | 0.040 |
Why?
|
| Masks | 1 | 2021 | 40 | 0.040 |
Why?
|
| Base Sequence | 1 | 2005 | 2899 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 52 | 0.040 |
Why?
|
| Rabbits | 3 | 2006 | 673 | 0.040 |
Why?
|
| Hospitals, Religious | 1 | 2020 | 6 | 0.040 |
Why?
|
| Catholicism | 1 | 2020 | 6 | 0.040 |
Why?
|
| Mutation | 1 | 2014 | 6226 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1547 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 309 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10933 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3409 | 0.040 |
Why?
|
| Phylogeny | 2 | 2017 | 763 | 0.040 |
Why?
|
| Salmonella enterica | 1 | 1998 | 9 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 3770 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2015 | 12991 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1998 | 117 | 0.030 |
Why?
|
| DNA, Bacterial | 2 | 2015 | 494 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 116 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2009 | 322 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 450 | 0.030 |
Why?
|
| Virulence | 2 | 2007 | 279 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 306 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 2 | 2009 | 391 | 0.030 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 2015 | 7 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Louisiana | 1 | 2015 | 136 | 0.030 |
Why?
|
| Enterotoxins | 1 | 2015 | 82 | 0.030 |
Why?
|
| Nanospheres | 1 | 2014 | 7 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 130 | 0.030 |
Why?
|
| Enterococcus | 1 | 2014 | 31 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2005 | 2674 | 0.030 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 30 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 102 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 102 | 0.030 |
Why?
|
| Metronidazole | 1 | 2014 | 156 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 94 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 177 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 49 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 365 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2013 | 119 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 197 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 234 | 0.020 |
Why?
|
| United States | 3 | 2018 | 11648 | 0.020 |
Why?
|
| Phospholipids | 1 | 2013 | 104 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 229 | 0.020 |
Why?
|
| Biofilms | 1 | 2013 | 98 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 761 | 0.020 |
Why?
|
| APACHE | 1 | 2011 | 50 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 416 | 0.020 |
Why?
|
| Species Specificity | 2 | 2005 | 541 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 222 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 1129 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1452 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 749 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 9952 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 370 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 149 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1178 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2009 | 280 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 767 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 3087 | 0.020 |
Why?
|
| Tuberculin | 1 | 2007 | 7 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2007 | 20 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3011 | 0.020 |
Why?
|
| Aerosols | 1 | 2007 | 64 | 0.020 |
Why?
|
| Gene Expression | 2 | 2004 | 1558 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 760 | 0.020 |
Why?
|
| Ruminants | 1 | 2005 | 2 | 0.020 |
Why?
|
| Nitrites | 1 | 2006 | 49 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1572 | 0.020 |
Why?
|
| Fishes | 1 | 2005 | 35 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 84 | 0.010 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 52 | 0.010 |
Why?
|
| Horses | 1 | 2005 | 104 | 0.010 |
Why?
|
| Primates | 1 | 2005 | 84 | 0.010 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2005 | 14 | 0.010 |
Why?
|
| Hospitalization | 1 | 2014 | 1898 | 0.010 |
Why?
|
| Chickens | 1 | 2005 | 302 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 124 | 0.010 |
Why?
|
| Sheep | 1 | 2005 | 230 | 0.010 |
Why?
|
| Polyproteins | 1 | 2004 | 8 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5163 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 48 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 152 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 2005 | 176 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 135 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 5007 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2005 | 171 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 569 | 0.010 |
Why?
|
| Pleural Cavity | 1 | 2004 | 6 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 264 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 468 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2004 | 236 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 133 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1284 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 3990 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 6440 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 743 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 876 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1180 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2718 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2006 | 822 | 0.010 |
Why?
|
| Cosmids | 1 | 1998 | 42 | 0.010 |
Why?
|
| Siderophores | 1 | 1998 | 10 | 0.010 |
Why?
|
| Salmonella | 1 | 1998 | 29 | 0.010 |
Why?
|
| Operon | 1 | 1998 | 48 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1998 | 180 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 18460 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 156 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 217 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 651 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 20535 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 811 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 615 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 441 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 4751 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 4680 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 17374 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 995 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 1799 | 0.010 |
Why?
|